An Early Phase II Trial with L-Deprenyl for the Treatment of Neuroleptic-Induced Parkinsonism
暂无分享,去创建一个
[1] M. Baron,et al. Platelet MAO activity and schizophrenic prognosis. , 1982, The American journal of psychiatry.
[2] J. R. de la Fuente,et al. Prolactin in psychiatry. , 1981, The American journal of psychiatry.
[3] M. Ackenheil,et al. Basal and Stimulated Levels of Prolactin, TSH and LH in Serum of Chronic Schizophrenic Patients, Long-term Treated with Neuroleptics , 1980, Pharmakopsychiatrie, Neuro-Psychopharmakologie.
[4] C. Marsden,et al. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs , 1980, Psychological Medicine.
[5] A. Erdös,et al. Endocrinological Changes in Patients with Sexual Dysfunction under Long-Term Neuroleptic Treatment , 1979, Pharmakopsychiatrie, Neuro-Psychopharmakologie.
[6] R. Weinshilboum. Serum dopamine beta-hydroxylase. , 1978, Pharmacological reviews.
[7] F. Owen,et al. Dopamine is a monoamine oxidase B substrate in man , 1977, Nature.
[8] Oliver H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[9] M. Baron,et al. Plasma DBH activity: relation to genetic factors in schizophrenia. , 1980, Communications in psychopharmacology.
[10] W. E. Fann,et al. On the coexistence of parkinsonism and tardive dyskinesia. , 1974, Diseases of the nervous system.